Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor

January 10, 2018 by Website Admin in

Moleculin today announced it has expanded the Company’s development pipeline for the treatment of acute myeloid leukemia with an immuno-stimulating STAT3 inhibitor.

Tweet

Share

Pin it

Previous StoryLivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development Next StoryLivaNova Initiates BELIEVE Aortic Heart Valve Study in the U.S. and Canada